TRV734 is a drug developed by Trevena, Inc. which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G protein signaling pathway over β-arrestin 2 recruitment.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.